Johanna Mercier (NBIX) converts 3,318 RSUs into Neurocrine Biosciences stock

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Johanna Mercier exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at a price of $0.00 per share. Following this derivative exercise, Mercier directly owns 6,853 shares of Neurocrine Biosciences common stock. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, making this a routine compensation-related transaction rather than an open-market purchase or sale.

Insider Trade Summary

3,318 shares exercised/converted

Mixed 2 txns

Insider Mercier Johanna

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	3,318	$0.00	--
Exercise	Common Stock	3,318	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock — 6,853 shares (Direct, null)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Key Figures

RSUs exercised: 3,318 units Common shares acquired via exercise: 3,318 shares Shares owned after transaction: 6,853 shares +1 more

4 metrics

RSUs exercised 3,318 units Restricted Stock Units converted to common stock on May 21, 2026

Common shares acquired via exercise 3,318 shares Shares received from RSU conversion at $0.00 per share

Shares owned after transaction 6,853 shares Total direct common stock holdings following the Form 4 transactions

RSU grant vesting 3,318 units RSU award granted May 21, 2025 and fully vested before conversion

Key Terms

Restricted Stock Unit, derivative security, exercise or conversion, vested

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise or conversion financial

"transaction_action: derivative exercise/conversion"

vested financial

"This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested."

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 07:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mercier Johanna

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND COURT

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/21/2026		M		3,318	A	$0	6,853	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0⁽¹⁾	05/21/2026		M			3,318	⁽²⁾	⁽²⁾	Common Stock	3,318	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX director Johanna Mercier report?

Johanna Mercier reported exercising 3,318 Restricted Stock Units into 3,318 shares of Neurocrine Biosciences common stock. This was a derivative exercise at $0.00 per share, reflecting routine conversion of vested equity compensation rather than an open-market stock purchase or sale.

How many NBIX shares does Johanna Mercier hold after this Form 4?

After the reported transactions, Johanna Mercier directly holds 6,853 shares of Neurocrine Biosciences common stock. This total reflects the addition of 3,318 shares from the RSU conversion reported, providing an updated view of her direct equity position in the company.

Were the NBIX transactions open-market buys or sells?

No, the NBIX transactions were not open-market buys or sells. They were coded “M,” indicating an exercise or conversion of derivative securities, specifically Restricted Stock Units, into common shares as part of equity compensation, with no reported market purchase or sale activity.

What are Restricted Stock Units (RSUs) in the NBIX filing for Johanna Mercier?

In this filing, each Restricted Stock Unit represents the right to receive one share of Neurocrine Biosciences common stock upon vesting. Mercier’s RSU award, granted on May 21, 2025, became fully vested and was then converted into 3,318 common shares on May 21, 2026.

Does the NBIX Form 4 show remaining derivative holdings for Johanna Mercier?

The Form 4 data show no remaining derivative holdings after this RSU conversion, as the derivative summary is empty and the reported RSU position falls to zero. This indicates the specific 3,318-unit RSU award has been fully converted into common stock.

What transaction code is used in the NBIX Form 4 for Johanna Mercier?

The Form 4 uses transaction code “M” for Johanna Mercier’s activity. This code denotes an exercise or conversion of a derivative security, here the Restricted Stock Units, into 3,318 shares of Neurocrine Biosciences common stock rather than a direct stock market purchase or sale.